ES2217492T3 - Anticuerpo monoclonal, especifico para el factor de coagulacion vii activado y su utilizacion. - Google Patents

Anticuerpo monoclonal, especifico para el factor de coagulacion vii activado y su utilizacion.

Info

Publication number
ES2217492T3
ES2217492T3 ES98124672T ES98124672T ES2217492T3 ES 2217492 T3 ES2217492 T3 ES 2217492T3 ES 98124672 T ES98124672 T ES 98124672T ES 98124672 T ES98124672 T ES 98124672T ES 2217492 T3 ES2217492 T3 ES 2217492T3
Authority
ES
Spain
Prior art keywords
factor vii
monoclonal antibody
activated
activated factor
fviia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98124672T
Other languages
English (en)
Spanish (es)
Inventor
Jurgen Dr. Rimisch
Wiegand Lang
Annette Feussner
Joachim Rider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
ZLB Behring GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZLB Behring GmbH filed Critical ZLB Behring GmbH
Application granted granted Critical
Publication of ES2217492T3 publication Critical patent/ES2217492T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES98124672T 1998-01-22 1998-12-24 Anticuerpo monoclonal, especifico para el factor de coagulacion vii activado y su utilizacion. Expired - Lifetime ES2217492T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19802139A DE19802139C1 (de) 1998-01-22 1998-01-22 Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
DE19802139 1998-01-22

Publications (1)

Publication Number Publication Date
ES2217492T3 true ES2217492T3 (es) 2004-11-01

Family

ID=7855234

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98124672T Expired - Lifetime ES2217492T3 (es) 1998-01-22 1998-12-24 Anticuerpo monoclonal, especifico para el factor de coagulacion vii activado y su utilizacion.

Country Status (9)

Country Link
US (2) US6479245B1 (enExample)
EP (1) EP0931793B1 (enExample)
JP (1) JP4422228B2 (enExample)
KR (1) KR100583537B1 (enExample)
AT (1) ATE261991T1 (enExample)
AU (1) AU742631B2 (enExample)
CA (1) CA2259724C (enExample)
DE (2) DE19802139C1 (enExample)
ES (1) ES2217492T3 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
JP4309656B2 (ja) * 2000-12-14 2009-08-05 ジェネンテック・インコーポレーテッド 原核生物で生成させた抗体とその用途
AU2002327192B2 (en) * 2001-07-03 2007-02-15 Oklahoma Medical Research Foundation Assay for measuring factor VIIa-antithrombin complexes
CA3135632A1 (en) 2019-04-17 2020-10-22 Novo Nordisk A/S Bispecific antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung

Also Published As

Publication number Publication date
CA2259724C (en) 2010-07-13
AU1318599A (en) 1999-08-12
JP4422228B2 (ja) 2010-02-24
AU742631B2 (en) 2002-01-10
KR19990068047A (ko) 1999-08-25
US20030003096A1 (en) 2003-01-02
CA2259724A1 (en) 1999-07-22
ATE261991T1 (de) 2004-04-15
KR100583537B1 (ko) 2006-05-26
DE19802139C1 (de) 1999-09-23
US6479245B1 (en) 2002-11-12
EP0931793A1 (de) 1999-07-28
DE59810998D1 (de) 2004-04-22
US6835817B2 (en) 2004-12-28
JPH11279199A (ja) 1999-10-12
EP0931793B1 (de) 2004-03-17

Similar Documents

Publication Publication Date Title
US7033590B1 (en) Factor IX/factor IXa activating antibodies and antibody derivatives
DE69223355T2 (de) Verfahren und Zusammensetzungen zum Nachweis von Serumproteasen, insbesondere für aktiviertes Protein C
US7863009B2 (en) Mutants of the factor VII-activating protease and detection methods using specific antibodies
US20050058640A1 (en) Factor IXa specific antibodies displaying factor VIIIa like activity
KR940002033B1 (ko) 단백질 c에 대해 특이성이 있는 단클론성 항체 및 항체의 분리방법
EP0690991B1 (en) Novel anticoagulant cofactor activity
US7439025B2 (en) Antibodies binding a gamma carboxyglutamic acid displaying epitope
ES2217492T3 (es) Anticuerpo monoclonal, especifico para el factor de coagulacion vii activado y su utilizacion.
Kaplan et al. Molecular mechanisms of fibrinolysis in man
Prydz et al. Factor X
KR100972943B1 (ko) 혈액 응고 인자 ⅶ-활성화 프로테아제에 대한 억제모노클로날 항체
Kumar et al. Inhibition of factor Xa-mediated procoagulant activity of human lung fibroblasts and pleural mesothelial cells
Seiffert et al. Prothrombin activation in rabbits
Takahashi et al. Detailed characterization of an anti-factor IX monoclonal antibody that neutralizes the prolonged ox brain prothrombin time of hemophilia BM by synthetic peptides
CZ200057A3 (cs) Monoklonální protilátky, fragmenty protilátek, jejich směsi nebo deriváty a jejich použití a buňky pro jejich exprimaci
JPH03200066A (ja) 活性化ヒトプロテインｃの測定方法
HU201844B (en) Immun adsorptive-amidolytic method for detecting plasminogen activator precursor (pro-uppa) and plasminogen activator (upa) of the human urine
JPH0195799A (ja) モノクローナル抗体および免疫化学的測定方法
Lawson Tissue factor dependent hemostasis
Leung The regulation of plasminogen activators by human minactivin, a plasminogen activator inhibitor (PAI-2)
MXPA99011382A (en) Ancrod specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and use of the same
JPH03187396A (ja) 抗体，抗体産生ハイブリドーマおよび抗体の用途